All In Biotech

NDA 050784 · Pfizer

Zithromax

Azithromycin · Oral

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

May 24, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

627

181 Phase 3, 43 recruiting

FAERS reports

19,146

13,050 serious, 1,467 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2026.

ZITHROMAX is a macrolide antibacterial drug indicated for treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: • Acute bacterial exacerbations of chronic bronchitis in adults ( 1.1 ) • Acute bacterial sinusitis in adults ( 1.1 ) • Uncomplicated skin and skin structure infections in adults ( 1.1 ) • Urethritis and cervicitis in adults ( 1.1 ) • Genital ulcer disease in men ( 1.1 ) • Acute otitis media in pediatric patients (6 months of age and older) ( 1.2 ) • Community-acquired pneumonia in adults and pediatric patients (6 months of age and older) ( 1.1 , 1.2 ) • Pharyngitis/tonsillitis in adults and pediatric patients (2 years of age and older) ( 1.1 , 1.2 ) Limitation of Use: ZITHROMAX is not recommended in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) 1.1 Indications in Adult Patients ZITHROMAX is indicated in adult patients for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: • Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . • Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis . or Streptococcus pneumoniae . • Community‑acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus...

Mechanism: Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4) ] Mechanism of Action Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit. Resistance Azithromycin demonstrates cross resistance with erythromycin. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZITHROMAX · AZITHROMYCIN EQ 500MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Azithromycin" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity1,997
  • dyspnoea1,466
  • drug ineffective1,199
  • nausea1,133
  • pain1,088
  • diarrhoea1,040
  • off label use1,014
  • fatigue1,013
  • pneumonia990
  • headache951
  • cough917
  • anxiety883

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004585
2005655
2006627
2007381
2008456
2009562
2010951
2011927
20121,059
2013740
2014905
20151,130
20161,333
20171,066
20181,335
20191,273
20201,191
2021904
2022774
2023716
2024639
2025545
2026392

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Apr 9, 2026

    Zithromax, Tablet, 500 mg (NDC 0069-3070-30). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zithromax* (Azithromycin)

2024 spending

$20K

Beneficiaries

708

1,040 claims

Per beneficiary

$29

$2.43 per unit

View as table
YearSpending
2020$50,470
2021$33,893
2022$26,479
2023$25,423
2024$20,386

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,833 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.